Abiopharma

🔍 Marshall Robert E (Executive)

Company: Evolv Technologies Holdings, Inc. (EVLV)

Report Date: 2026-06-01

Detailed Transactions and Holdings:

• Acquired 136,363 shares of Class A Common Stock (Direct)
  Date: 2026-06-01 | Code: M | equity_swap_involved: 0 | shares_owned_after: 143,363.00 | transaction_form_type: 4
• Sold 62,067 shares of Class A Common Stock at $6.85 per share (Direct)
  Date: 2026-06-02 | Code: S | equity_swap_involved: 0 | shares_owned_after: 81,296.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 136,363 shares of Restricted Stock Units (Derivative)
  Date: 2026-06-01 | Code: M | equity_swap_involved: 0 | shares_owned_after: 272,727.00 | transaction_form_type: 4 | Footnotes: F3, F4, F3

Footnotes:

• F1: The sale reported in the Form 4 was effected solely with the intent to cover withholding taxes in connection with the vesting of RSUs.
• F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
• F3: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A common stock. The RSUs have no expiration date.
• F4: The RSUs vest in three equal annual installments commencing on March 1, 2026.